178 related articles for article (PubMed ID: 33815117)
1. The Efficacy of Tocilizumab in the Treatment of Patients with Refractory Immune-Mediated Necrotizing Myopathies: An Open-Label Pilot Study.
Li S; Li W; Jiang W; He L; Peng Q; Wang G; Lu X
Front Pharmacol; 2021; 12():635654. PubMed ID: 33815117
[No Abstract] [Full Text] [Related]
2. Pathogenic role of anti-signal recognition protein and anti-3-Hydroxy-3-methylglutaryl-CoA reductase antibodies in necrotizing myopathies: Myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies.
Arouche-Delaperche L; Allenbach Y; Amelin D; Preusse C; Mouly V; Mauhin W; Tchoupou GD; Drouot L; Boyer O; Stenzel W; Butler-Browne G; Benveniste O
Ann Neurol; 2017 Apr; 81(4):538-548. PubMed ID: 28224701
[TBL] [Abstract][Full Text] [Related]
3. Rituximab in the treatment of immune-mediated necrotizing myopathy: a review of case reports and case series.
Xiong A; Yang G; Song Z; Xiong C; Liu D; Shuai Y; He L; Zhang L; Guo Z; Shuai S
Ther Adv Neurol Disord; 2021; 14():1756286421998918. PubMed ID: 33786066
[TBL] [Abstract][Full Text] [Related]
4. High levels of natural killer cells are associated with response to tocilizumab in patients with severe rheumatoid arthritis.
Daïen CI; Gailhac S; Audo R; Mura T; Hahne M; Combe B; Morel J
Rheumatology (Oxford); 2015 Apr; 54(4):601-8. PubMed ID: 25231180
[TBL] [Abstract][Full Text] [Related]
5. Relationship between change in physical activity and in clinical status in patients with idiopathic inflammatory myopathy: A prospective cohort study.
Landon-Cardinal O; Bachasson D; Guillaume-Jugnot P; Vautier M; Champtiaux N; Hervier B; Rigolet A; Aggarwal R; Benveniste O; Hogrel JY; Allenbach Y
Semin Arthritis Rheum; 2020 Oct; 50(5):1140-1149. PubMed ID: 32920327
[TBL] [Abstract][Full Text] [Related]
6. Immune-Mediated Necrotizing Myopathy.
Pinal-Fernandez I; Casal-Dominguez M; Mammen AL
Curr Rheumatol Rep; 2018 Mar; 20(4):21. PubMed ID: 29582188
[TBL] [Abstract][Full Text] [Related]
7. Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity.
Pinal-Fernandez I; Casal-Dominguez M; Carrino JA; Lahouti AH; Basharat P; Albayda J; Paik JJ; Ahlawat S; Danoff SK; Lloyd TE; Mammen AL; Christopher-Stine L
Ann Rheum Dis; 2017 Apr; 76(4):681-687. PubMed ID: 27651398
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of tocilizumab in Korean patients with active rheumatoid arthritis.
Baek HJ; Lim MJ; Park W; Park SH; Shim SC; Yoo DH; Kim HA; Lee SK; Lee YJ; Park YE; Cha HS; Song YW
Korean J Intern Med; 2019 Jul; 34(4):917-931. PubMed ID: 29334721
[TBL] [Abstract][Full Text] [Related]
9. Immune-mediated necrotizing myopathy is characterized by a specific Th1-M1 polarized immune profile.
Preuße C; Goebel HH; Held J; Wengert O; Scheibe F; Irlbacher K; Koch A; Heppner FL; Stenzel W
Am J Pathol; 2012 Dec; 181(6):2161-71. PubMed ID: 23058368
[TBL] [Abstract][Full Text] [Related]
10. Potential Pathogenic Role of Anti-Signal Recognition Protein and Anti-3-hydroxy-3-methylglutaryl-CoA Reductase Antibodies in Immune-Mediated Necrotizing Myopathies.
Ladislau L; Arouche-Delaperche L; Allenbach Y; Benveniste O
Curr Rheumatol Rep; 2018 Aug; 20(9):56. PubMed ID: 30074107
[TBL] [Abstract][Full Text] [Related]
11. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis.
Shimamoto K; Ito T; Ozaki Y; Amuro H; Tanaka A; Nishizawa T; Son Y; Inaba M; Nomura S
J Rheumatol; 2013 Jul; 40(7):1074-81. PubMed ID: 23637318
[TBL] [Abstract][Full Text] [Related]
12. [Autoantibodies of Inflammatory Myopathies: Update].
Suzuki S
Brain Nerve; 2016 Dec; 68(12):1443-1451. PubMed ID: 27916754
[TBL] [Abstract][Full Text] [Related]
13. Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up.
Zong M; Dorph C; Dastmalchi M; Alexanderson H; Pieper J; Amoudruz P; Barbasso Helmers S; Nennesmo I; Malmström V; Lundberg IE
Ann Rheum Dis; 2014 May; 73(5):913-20. PubMed ID: 23625983
[TBL] [Abstract][Full Text] [Related]
14. Necrotizing myopathies: an update.
Quinn C; Salameh JS; Smith T; Souayah N
J Clin Neuromuscul Dis; 2015 Mar; 16(3):131-40. PubMed ID: 25695918
[TBL] [Abstract][Full Text] [Related]
15. Immune Mediated Necrotizing Myopathy: Where do we Stand?
Mohammed AGA; Gcelu A; Moosajee F; Botha S; Kalla AA
Curr Rheumatol Rev; 2019; 15(1):23-26. PubMed ID: 29623846
[TBL] [Abstract][Full Text] [Related]
16. Immune-mediated myopathy related to anti 3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies as an emerging cause of necrotizing myopathy induced by statins.
Lahaye C; Beaufrére AM; Boyer O; Drouot L; Soubrier M; Tournadre A
Joint Bone Spine; 2014 Jan; 81(1):79-82. PubMed ID: 23953224
[TBL] [Abstract][Full Text] [Related]
17. Peculiar clinicopathological features of immune-mediated necrotizing myopathies.
Allenbach Y; Benveniste O
Curr Opin Rheumatol; 2018 Nov; 30(6):655-663. PubMed ID: 30239349
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of adrenocorticotropic hormone gel in refractory dermatomyositis and polymyositis.
Aggarwal R; Marder G; Koontz DC; Nandkumar P; Qi Z; Oddis CV
Ann Rheum Dis; 2018 May; 77(5):720-727. PubMed ID: 29237618
[TBL] [Abstract][Full Text] [Related]
19. Tocilizumab in refractory adult Still's disease.
Puéchal X; DeBandt M; Berthelot JM; Breban M; Dubost JJ; Fain O; Kahn JE; Lequen L; Longy-Boursier M; Perdriger A; Schaeverbeke T; Toussirot E; Sibilia J;
Arthritis Care Res (Hoboken); 2011 Jan; 63(1):155-9. PubMed ID: 20740616
[TBL] [Abstract][Full Text] [Related]
20. Integrated Diagnosis Project for Inflammatory Myopathies: An association between autoantibodies and muscle pathology.
Suzuki S; Uruha A; Suzuki N; Nishino I
Autoimmun Rev; 2017 Jul; 16(7):693-700. PubMed ID: 28479486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
